iBio Launches New Sterile Fill-Finish Services
June 03 2019 - 8:00AM
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today
introduced new cGMP sterile fill-finish capabilities for
pharmaceutical products, including monoclonal antibodies, viral
vectors, and other biologics. Designed for clients with preclinical
and clinical stage programs, the operation is housed in the
Company’s 135,000 square foot CDMO facility located in Bryan,
Texas.
“Providing Fill-Finish services is a natural extension of iBio’s
FastPharming™ biologics CDMO capabilities,” said
Robert Kay, CEO. “Given our ability to quickly deliver GMP and
research quantities of active pharmaceutical ingredient (API), the
addition of the fill-finish operation completes our rapid,
end-to-end service offering.”
The sterile liquid fill-finish operation will incorporate
in-line labeling, allowing serialization of vials as they are
filled. Initial capacity supports 100 – 2,500 vials runs,
with plans to expand to 15,000. iBio will be presenting more
details on its 5mL vial and 100mL bottle filling services at BIO
2019 in Philadelphia, PA, taking place June 3-6.
“We understand the needs of early stage companies, who often
face moving targets for their timelines and support requirements,”
commented Nicolas Taquet, Vice President, Biopharmaceutical
Manufacturing. “It is often problematic trying to identify
available capacity for high-quality, small volume filling. We’re
now in position to fill that need for our clients.”
About iBio
iBio is a global leader in plant-based biopharmaceutical
contract development and manufacturing services. With iBio’s
FastPharming™ protein expression and glycan
engineering technologies, consistently high-quality biologics can
be produced rapidly in plants using automated hydroponic systems at
iBio CDMO, LLC in Bryan, Texas. In addition to GMP contract
manufacturing, iBio also offers process development, bioanalytical,
and fill-finish services, along with regulatory and facility design
consulting as part of an end-to-end solution. For more information,
visit www.ibioinc.com.
About BIO International
BIO, taking place June 3-6, 2019 in Philadelphia, PA, features
the latest trends, technology, companies, and breakthrough ideas in
biotech and pharma. BIO is expecting nearly 16,000 attendees with
1,800 exhibiting companies and delegations from 67 countries Visit
iBIO at Booth #3059. For more information about BIO, visit
https://convention.bio.org/bio-exhibition/.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC.
MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS
INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE
FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE
COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE
NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF
PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD
AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE
COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contact:
Stephen KilmerInvestor Relations(646) 274-3580
skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024